← Our writersEvidence & trials
Laura Bennett
Reads the methods section, and tells you when the endpoint was a blood level rather than a benefit.
Laura Bennett is a pen name used by a writer at NAD Picks. Laura covers the primary NAD⁺ literature — the randomized precursor trials, what they powered for, and the gap between raising a biomarker and improving an outcome. Every claim on a page under this byline carries a citation you can open and check yourself.
What they cover
- Randomized trials of NAD⁺ precursors
- Nicotinamide riboside and NMN clinical evidence
- Surrogate biomarkers versus clinical endpoints
- Effect size and confidence interval interpretation
- Evidence grading: human, animal, in-vitro
- Primary literature appraisal
Articles by Laura Bennett
5 pieces- NAD⁺ benefits: what the trials measured, and the one they tested that did not appearEvidence
- NAD⁺ injections before and after: what those photos can and cannot tell youEvidence
- Does NAD⁺ help with weight loss? What one trial found, and why it is not the claimEvidence
- NAD⁺ side effects: what the safety trials show, and where there are noneSafety
- NAD⁺ vs NAC: two acronyms, two completely different moleculesEvidence